OpGen (NASDAQ:OPGN) is a precision medicine company that develops and commercializes molecular diagnostics and informatics solutions to combat infectious diseases. The company’s core mission focuses on the rapid identification of antibiotic-resistant pathogens and the optimization of antibiotic therapy through advanced genomic testing. OpGen’s technology platforms are designed to deliver actionable diagnostic information to clinicians and microbiology laboratories, with the goal of improving patient outcomes and supporting antimicrobial stewardship programs.
OpGen’s flagship product, the Acuitas AMR Gene Panel, leverages real-time polymerase chain reaction (PCR) to detect key genes associated with antibiotic resistance across Gram-negative bacteria. This platform is compatible with a broad range of PCR instruments commonly used in clinical laboratories. In addition, OpGen offers the Unyvero™ System through its acquisition of Curetis GmbH, providing a fully automated, multiplexed syndromic testing solution for respiratory and blood infections. The Unyvero cartridges enable rapid pathogen and resistance marker identification directly from clinical samples, reducing time to diagnosis and guiding targeted therapy.
The company serves healthcare institutions, clinical laboratories and public health organizations in the United States and Europe, with a growing footprint in Asia-Pacific markets. OpGen collaborates with hospitals, research institutions and governmental agencies to deploy its diagnostic platforms in both routine clinical workflows and epidemiological surveillance programs. By integrating molecular diagnostics data with bioinformatics tools, OpGen supports microbiologists and infectious disease specialists in tracking resistance trends and optimizing therapeutic strategies.
Founded in 1998 under the original name GenoSensor, OpGen rebranded in 2008 to reflect its expanded focus on genomics-driven solutions. Over the years, the company has built a leadership team with deep expertise in molecular biology, infectious diseases and diagnostics commercialization. Leveraging strategic partnerships and a robust intellectual property portfolio, OpGen continues to advance its technology pipeline and expand market access for its precision diagnostic offerings.
